Eisai Co Ltd represents a set of core values and a corporate philosophy that guides its operations. The company is committed to human health care and believes in "human health care" (hhc) as an essential principle. Eisai aims to contribute to the well-being of patients through innovative pharmaceuticals and healthcare services. The company emphasizes the importance of gaining trust from patients, healthcare professionals, and the global community while striving for continuous improvement. Eisai Co Ltd focuses on creating value for patients and society, matching scientific competence with a compassionate approach. Emphasizing patient-centricity, Eisai Co Ltd constantly endeavors to fulfill its mission of providing effective treatments and improving the quality of life for patients worldwide.

Eisai Co Ltd is primarily present in various countries and regions across the globe. The company has significant presence in its home country, Japan, where it is headquartered. Furthermore, Eisai Co Ltd has expanded its operations to the United States, Europe, Asia, and other key markets. With its strong focus on global growth, Eisai Co Ltd has established subsidiaries and affiliates in multiple countries, enabling it to reach a wider customer base and cater to diverse markets.

Eisai Co Ltd, a renowned pharmaceutical company, has achieved notable milestones throughout its history. The company successfully developed and introduced innovative healthcare solutions, contributing to advancements in medicine. Eisai Co Ltd made significant strides in the discovery and development of drugs for various therapeutic areas, including oncology, neurology, and gastrointestinal disorders. It received numerous regulatory approvals for its groundbreaking medications, enhancing patient care worldwide. Eisai Co Ltd's relentless commitment to research and development has resulted in the introduction of groundbreaking treatments, earning recognition and trust from both healthcare professionals and patients alike.

Eisai Co Ltd is a renowned pharmaceutical company founded in 1941 in Japan. With a rich history spanning over 80 years, Eisai has established itself as a global leader in the healthcare industry. The company focuses on discovering, developing, and marketing innovative medications to address various medical needs. Eisai is committed to improving the lives of patients worldwide and has made significant contributions to research and development in the areas of neurology, oncology, and gastrointestinal disorders. Known for its dedication to patient-centered care, Eisai continues to make strides in advancing medical science and delivering effective therapeutic solutions to support human health.

Some of the main competitors of Eisai Co Ltd in the market include pharmaceutical companies such as Pfizer, Roche, Novartis, and Gilead Sciences.

Eisai Co Ltd is primarily active in the pharmaceutical industry.

The business model of Eisai Co Ltd involves being a global pharmaceutical company focused on the discovery, development, and marketing of innovative medicines. Eisai Co Ltd aims to address unmet medical needs in areas such as neurology and oncology, along with supportive care. With a patient-centered approach, the company combines its expertise in research and development with strategic partnerships to deliver solutions for improved healthcare outcomes. Eisai Co Ltd emphasizes creating sustainable value and contributing to society through its pharmaceutical products and services.

The Eisai Co P/E ratio is 24.08.

The Eisai Co P/S ratio is 1.42.

The Quality Investing for Eisai Co is 3/10.

The Eisai Co revenue is 789.4 B JPY.

The Eisai Co profit is 46.43 B JPY.

Eisai Co Ltd is a company specializing in the research, development, production, and marketing of pharmaceuticals and preparations. The Japanese company was founded in 1949 and is headquartered in Tokyo. The company is divided into several business divisions to manage its product lines. The "Neurology" division specializes in the treatment of Alzheimer's, Parkinson's, and epilepsy, offering a wide range of medications for these diseases. Eisai's "Oncology" division focuses on developing drugs for the treatment of cancer. The company works to develop innovative therapies that improve the quality of life and cure cancer patients. Products in this area include Lenvima, Halaven, and Kisplyx. Eisai's "Gastroenterology" division offers drugs for the treatment of gastrointestinal disorders, including functional dyspepsia, reflux esophagitis, enteritis, colitis, and stool regulation. This includes drugs such as Aciphex and Targaxan. Another business division of Eisai is the "Integumentary System," which focuses on products for the treatment of skin diseases such as psoriasis, acne, and atopic dermatitis. This includes products like Tazorac and Erivedge. In addition, Eisai operates its own research and development department to bring innovative drugs to the market. The company collaborates with scientific and medical partners worldwide and continuously invests in the research and development of new drugs. Furthermore, in recent years, the company has expanded its presence in the Asia-Pacific region and North America. Eisai also has joint ventures and partnerships with other companies to bring innovative products to the market, optimizing product development, production, and marketing. An example of this is the collaboration with Biogen for the development and marketing of therapies for Alzheimer's disease. Overall, Eisai specializes in providing innovative and high-quality pharmaceuticals and therapies to improve the lives of patients worldwide. The company is dedicated to research and development of new products and has a wide range of business divisions and partnerships to expand its portfolio and global presence.

Eisai Co pays a dividend of 160 JPY distributed over 2 payouts per year.

Eisai Co pays out a dividend 2 times a year.

The ISIN of Eisai Co is JP3160400002.

The WKN of Eisai Co is 855526.

The ticker of Eisai Co is 4523.T.

Over the past 12 months, Eisai Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 2.03 %. For the coming 12 months, Eisai Co is expected to pay a dividend of 80.57 JPY.

The current dividend yield of Eisai Co is 2.03 %.

Eisai Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

Eisai Co paid dividends every year for the past 22 years.

For the upcoming 12 months, dividends amounting to 80.57 JPY are expected. This corresponds to a dividend yield of 2.04 %.

Eisai Co is assigned to the 'Health' sector.

To receive the latest dividend of Eisai Co from 6/1/2025 amounting to 80 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

The last dividend was paid out on 6/1/2025.

In the year 2024, Eisai Co distributed 160 JPY as dividends.

The dividends of Eisai Co are distributed in JPY.